We would love to hear your thoughts about our site and services, please take our survey here.
RMM the market and interest in TYK2/JAK1 programmes is very high and emphasised due to COVID. I think with all the exposure in various media forums over the weekend it is significant.
SAR IP also supported recently by the Nature publication that TYK2 has been Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 plus potential target for Therapy.
SAR also investigating 1801 as protection/treatment against bacterial pneumonia following SARS-CoV-2 infection.
IMHO this TYK2/JAK1 programme and associated IP is a matter of national importance, therefore funding will not be a hurdle as it will be paid for by potential TO candidate or Boris will pay for P1 and P2. In any case 1801 will be entering into human studies in the near future.
The rise in sp is due to the above; 3.5p soon; as Ahfam3 says Many Happy Returns Chaps
Sareum's CEO, Dr Tim Mitchell, commented:
"We will review the data and progress made with the programme by our Chinese partner over the coming weeks and will evaluate options for re-partnering the FLT3 programme. While early studies with our FLT3+Aurora kinase inhibitors were promising, formulation continues to be a challenge. Our clear priority focus remains on advancing our proprietary TYK2/JAK1 programmes and, in the near-term, on completing the preclinical work needed for the first Clinical Trial Application during the first quarter of the year. Achieving this important milestone will be a key step in generating shareholder value from our TYK2/JAK1 pipeline."
A key step in generating shareholder value. For me this is the key take away from the RNS; couldn't have been more positive. GLA
Fadec let others make their own opinions by checking your posting history. Imho you knowledge on how a market works is limited or you are playing a very good dumb game. I believe I am qualified to call it out, I worked for a very large investment bank in the 90s. BR
Fadec you may know a bit about the science but your track record on comments on the market are very questionable. Plain sailing the last 10 months ? Sorry but I don’t call covid impacts pnn mm sin sailing particularly when the market didn’t understand and thought vaccines were going to immediately save the day. What we have know is FLT3 out of Chinese hands and a clear pathway now for a TO associated with 1802/1801. Much much easier. As I Stated there was very little value built into the sp from FLT3. The smart money is coming for TYK2. Drop overdone
What is the estimated timeframe for the CTA approval for phase1 considering nearly 6 weeks have past? My guess is that it won’t take that long given the urgency of the situation would be good to get some expert opinion on this chaps?
Soundreason you are a paid troll. if that is directed at me I have made no losses as bud have held here since 2016. Good day and go back to the troll farm and close the gate behind you this time. Go and suck the pig swill up.
You have absolutely no idea.
Spectoacum I have given up reading your trash no idea what you are going on about to be fair. Do you realise that 1801/1802 about to go into P1 and most likely funded by Boris.
Potnak imho the recent share price rally is driven by 1801/1802 and licensing deal or TO. For me that is the key asset and the rub was FLT3 and how where they going to deal with this in a TO deal. 737 is straight forward as clear cut .